Mirtazapine (Page 6 of 10)

Nursing Mothers

Because some mirtazapine may be excreted into breast milk, caution should be exercised when mirtazapine tablets are administered to nursing women.

Pediatric Use

Safety and effectiveness in the pediatric population have not been established (see BOXED WARNING and WARNINGS, Clinical Worsening and Suicide Risk). Two placebo-controlled trials in 258 pediatric patients with MDD have been conducted with mirtazapine tablets, and the data were not sufficient to support a claim for use in pediatric patients. Anyone considering the use of mirtazapine in a child or adolescent must balance the potential risks with the clinical need.

In an 8-week-long pediatric clinical trial of doses between 15 mg/day to 45 mg/day, 49% of mirtazapine-treated patients had a weight gain of at least 7%, compared to 5.7% of placebo-treated patients. The mean increase in weight was 4 kg (2 kg SD) for mirtazapine-treated patients versus 1 kg (2 kg SD) for placebo-treated patients (see PRECAUTIONS, Increased Appetite/Weight Gain).

Geriatric Use

Approximately 190 elderly individuals (greater than or equal to 65 years of age) participated in clinical studies with mirtazapine tablets. This drug is known to be substantially excreted by the kidney (75%), and the risk of decreased clearance of this drug is greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection. Sedating drugs may cause confusion and over-sedation in the elderly. No unusual adverse age-related phenomena were identified in this group. Pharmacokinetic studies revealed a decreased clearance in the elderly. Caution is indicated in administering mirtazapine to elderly patients (see CLINICAL PHARMACOLOGY and DOSAGE AND ADMINISTRATION).

ADVERSE REACTIONS

Associated with Discontinuation of Treatment

Approximately 16% of the 453 patients who received mirtazapine tablets in U.S. 6-week controlled clinical trials discontinued treatment due to an adverse experience, compared to 7% of the 361 placebo-treated patients in those studies. The most common events (greater than or equal to 1%) associated with discontinuation and considered to be drug related (i.e., those events associated with dropout at a rate at least twice that of placebo) are included in Table 2.

Table 2: Common Adverse Events Associated with Discontinuation of Treatment in 6-Week U.S. Mirtazapine Trials

Adverse

Event

Percentage of Patients

Discontinuing with Adverse Event

Mirtazapine

(n=453)

Placebo

(n=361)

Somnolence

10.4%

2.2%

Nausea

1.5%

0%

Commonly Observed Adverse Events in U.S. Controlled Clinical Trials

The most commonly observed adverse events associated with the use of mirtazapine tablets (incidence of 5% or greater) and not observed at an equivalent incidence among placebo-treated patients (mirtazapine incidence at least twice that for placebo) are listed in Table 3.

Table 3: Common Treatment-Emergent Adverse Events Associated with the Use of Mirtazapine in 6-Week U.S. Trials

Adverse

Event

Percentage of Patients Reporting

Adverse Event

Mirtazapine

(n=453)

Placebo

(n=361)

Somnolence

54%

18%

Increased Appetite

17%

2%

Weight Gain

12%

2%

Dizziness

7%

3%

Adverse Events Occurring at an Incidence of 1% or More Among Mirtazapine-Treated Patients

Table 4 enumerates adverse events that occurred at an incidence of 1% or more, and were more frequent than in the placebo group, among mirtazapine tablet-treated patients who participated in short-term U.S. placebo-controlled trials in which patients were dosed in a range of 5 mg/day to 60 mg/day. This table shows the percentage of patients in each group who had at least 1 episode of an event at some time during their treatment. Reported adverse events were classified using a standard COSTART-based dictionary terminology.

The prescriber should be aware that these figures cannot be used to predict the incidence of side effects in the course of usual medical practice where patient characteristics and other factors differ from those which prevailed in the clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other investigations involving different treatments, uses, and investigators. The cited figures, however, do provide the prescribing physician with some basis for estimating the relative contribution of drug and non-drug factors to the side-effect incidence rate in the population studied.

Table 4: Incidence of Adverse Clinical Experiences * (greater than or equal to 1%) in Short-Term U.S. Controlled Studies
*
Events reported by at least 1% of patients treated with mirtazapine are included, except the following events which had an incidence on placebo greater than or equal to mirtazapine: headache, infection, pain, chest pain, palpitation, tachycardia, postural hypotension, nausea, dyspepsia, diarrhea, flatulence, insomnia, nervousness, libido decreased, hypertonia, pharyngitis, rhinitis, sweating, amblyopia, tinnitus, taste perversion.

Body System

Adverse Clinical Experience

Mirtazapine

(n=453)

Placebo

(n=361)

Body as a Whole

Asthenia

8%

5%

Flu Syndrome

5%

3%

Back Pain

2%

1%

Digestive System

Dry Mouth

25%

15%

Increased Appetite

17%

2%

Constipation

13%

7%

Metabolic and Nutritional Disorders

Weight Gain

12%

2%

Peripheral Edema

2%

1%

Edema

1%

0%

Musculoskeletal System

Myalgia

2%

1%

Nervous System

Somnolence

54%

18%

Dizziness

7%

3%

Abnormal Dreams

4%

1%

Thinking Abnormal

3%

1%

Tremor

2%

1%

Confusion

2%

0%

Respiratory System

Dyspnea

1%

0%

Urogenital System

Urinary Frequency

2%

1%

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2020. All Rights Reserved.